Sanofi (France)
NEWS
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
After roaring into February with positive data in five different indications, Regeneron and Sanofi announced today a late-stage Dupixent trial has been halted due to futility.
Star Therapeutics has exited stealth mode and announced a spin-off company, Electra Therapeutics.
For 2021, with $6.19 billion in sales the monoclonal antibody counted for a little less than one-third of Regeneron’s overall $16.07 billion revenue.
After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of its corporate umbrella supporting its three-year-old “Play to Win” strategy.
The FDA had accepted the sBLA in September 2021 under priority review status.
JOBS
IN THE PRESS